Concentra Group Holdings 株価情報 (NYSE: CON)

Concentra Group Holdings (NYSE:CON) 株価情報

Concentra Group Holdings

Concentra Group Holdings Parent Inc is a company providing occupational and consumer health services through occupational health centers and onsite clinics. Their services include workers' compensation injury care, employer services, urgent care, clinical testing, wellness programs, and preventative care.

Concentra Group Holdings Parent, Inc. Common Stock

Concentra Group Holdings Parent Inc

CONUN

Conectisys Corp

GraniteShares 1x Short COIN Daily ETF

CELLTRION INC ORD by Celltrion, Inc.

GraniteShares 2x Long COIN Daily ETF

CoinSmart Financial Inc

Conn's Inc

Convergence

NICKEL 28 CAP CORP by NICKEL 28 CAP CORP.

Nickel 28 Capital Corp

CONX Corp Units (1 Ord Share Class A & 1/4 War)

CONX Corp

Tidal ETF Trust II YieldMax COIN Option Income Strategy ETF

InfuSystem is providing annual guidance for the full year 2025 with net revenue growth estimated to be in the 8% to 10% range. We are also forecasting Adjusted EBITDA margin (non-GAAP) to be in the high-teens, exceeding the Company's margin of 18.8% in 2024, this despite the planned continued investment in the Company's information technology systems. The Company intends to update its annual guidance throughout the year.&nbsp;

Earnings

News

Guidance

Health Care

General

INFU

InfuSystem Estimates 2025 With Net Revenue Growth Of 8% To 10%, With Adjusted EBITDA Margin To Be In The High-Teens

UBS analyst William Grippin downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Buy to Neutral and lowers the price target from $5 to $0.65.

Downgrades

Price Target

Analyst Ratings

NOVA

UBS Downgrades Sunnova Energy Intl to Neutral, Lowers Price Target to $0.65

HC Wainwright &amp; Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and maintains $51 price target.

Reiteration

SNDX

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $51 Price Target

Target Reports Q4 Comparable Sales Growth Of 1.5%, Reflected Strong Traffic And Digital Performance

Earnings Beats

Earnings Misses

Sea Q4 2024 GAAP EPS $0.39 Misses $0.40 Estimate, Sales $4.950B Beat $4.623B Estimate

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.07 by 42.86 percent. The company reported quarterly sales of $33.85 million which missed the analyst consensus estimate of $34.90 million by 3.02 percent. This is a 6.54 percent increase over sales of $31.77 million the same period last year.

InfuSystems Holdings Q4 2024 GAAP EPS $0.04 Misses $0.07 Estimate, Sales $33.85M Miss $34.90M Estimate

AI Detection firm, Copyleaks has found that the text generated by DeepSeek-R1 and OpenAI&#8217;s ChatGPT has &#8220;Stylistic overlaps&#8221; in 74.2% of instances.
What Happened: A study conducted by Copyleaks showed that Chinese start-up firm, DeepSeek-R1&#8217;s text generation closely mirrored OpenAI&#8217;s style in over 74% of cases. This suggests that DeepSeek may have relied on OpenAI's model during its training without authorization, according to the report.
The study employed three AI classifiers to accurately analyze stylistic fingerprints, allowing for model-specific attribution. This plays a vital role in safeguarding intellectual property and fostering ethical AI development.
DeepSeek and OpenAI did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
Interestingly, the written text produced by most other models was easily identifiable as unique to each one, except DeepSeek. For instance, Microsoft&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Phi-4 and Grok-1 models exhibited no similarities to existing models, confirming it was trained independently.
The majority of DeepSeek&#8217;s outputs were identified as being generated by OpenAI&#8217;s models. &nbsp;&#8220;While this similarity doesn&#8217;t&nbsp;definitively prove or declare DeepSeek&nbsp;as a derivative, it does&nbsp;raise questions about its development,&#8221; said&nbsp;Shai Nisan,&nbsp;Head of data science at&nbsp;Copyleaks.
SEE ALSO: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44075328/eric-trump-says-timing-of-strategic-bitcoin-xrp-cardano-reserve-announcement-was-a-win-for-retail-investors">Eric Trump Says Timing Of Strategic Bitcoin, XRP, Cardano Reserve Announcement Was A &#8216;Win&#8217; For Retail Investors</a>
Why It Matters: This revelation comes at a time when the AI industry is under scrutiny. Recently, Singapore authorities launched an investigation into potential <a href="https://www.benzinga.com/25/03/44076579/singapore-investigates-potential-fraud-in-nvidia-ai-chip-shipments-the-question-is-whether-malaysia-was-a-final-destination">fraudulent activities </a>related to the shipment of&nbsp;Nvidia Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips.
Furthermore,&nbsp;Dario Amodei, CEO of Jeff Bezos-backed Anthropic, has called for stronger U.S. AI safeguards. He warned that autocratic regimes like <a href="https://www.benzinga.com/25/03/44069535/anthropic-ceo-dario-amodei-pushes-for-stronger-us-ai-safeguards-saying-autocracies-like-china-and-russia-could-use-ai-to-expand-their-power">China and Russia </a>could use AI to enhance their control and military capabilities.
While the possibility of both AI models being trained using intersecting datasets cannot be ruled out, there could be deeper nuances. "Even if large language models draw from overlapping datasets, AI fingerprinting remains crucial. The sheer variety of elements—such as architecture, fine-tuning methods and generation techniques—ensures that each LLM develops a distinct writing style,&#8221; explains Nisan.
The DeepSeek-R1 and OpenAI similarity issue underscores the need for clear regulations and transparency in AI development to prevent potential misuse and protect intellectual property. It also brings into question DeepSeek R1&#8217;s perceived level of innovation.
Nisan cautioned that this could have significant implications for the AI industry, if not regulated.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/03/44101621/deepseek-loses-top-spot-as-tencents-yuanbao-ai-becomes-no-1-iphone-app-amid-intensifying-ai-battle">DeepSeek Loses Top Spot As Tencent&#8217;s Yuanbao AI Becomes The Top iPhone App In China Amid Intensifying AI Battle</a></li>
</ul>
Image Via Midjourney, Shutterstock

Equities

Markets

Tech

MSFT

NVDA

74% Of DeepSeek's Output Mimics OpenAI's ChatGPT, New Study Reveals: 'It Does Raise Questions About Its Development'

Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) reported quarterly earnings of $2.41 per share which beat the analyst consensus estimate of $2.26 by 6.64 percent. This is a 19.13 percent decrease over earnings of $2.98 per share from the same period last year. The company reported quarterly sales of $30.91 billion which beat the analyst consensus estimate of $30.84 billion by 0.23 percent. This is a 3.15 percent decrease over sales of $31.92 billion the same period last year.

Target Q4 2024 Adj EPS $2.41 Beats $2.26 Estimate, Sales $30.91B Beat $30.84B Estimate

UBS analyst William Grippin downgrades Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) from Buy to Sell and lowers the price target from $37 to $8.

AMRC

UBS Downgrades Ameresco to Sell, Lowers Price Target to $8

HC Wainwright &amp; Co. analyst Mike Colonnese maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and lowers the price target from $35 to $30.

HC Wainwright & Co. Maintains Buy on Hut 8, Lowers Price Target to $30

<a href="https://www.wsj.com/business/deals/honeywells-transformation-continues-with-2-2-billion-deal-for-pump-maker-b4695197" title="https://www.wsj.com/business/deals/honeywells-transformation-continues-with-2-2-billion-deal-for-pump-maker-b4695197">https://www.wsj.com/business/deals/honeywells-transformation-continues-with-2-2-billion-deal-for-pump-maker-b4695197</a>

Wall Street Journal Reported Honeywell Nears $2.2B All-Cash Deal to Acquire Pump Maker Sundyne From Warburg Pincus, Announcement Expected Tuesday

Albertsons Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) has <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44093556/albertsons-companies-inc-announces-ceo-succession-plan" rel="noreferrer noopener">announced a major leadership </a>shift as CEO Vivek Sankaran plans to retire on May 1, 2025.
Susan Morris, who is currently the Executive Vice President and Chief Operations Officer, will step into the role. On the same day, Morris will also assume a seat on the company's Board of Directors, replacing Sankaran.
With nearly 40 years of experience in the grocery retail sector, Susan Morris has held several leadership positions within Albertsons.
Since January 2018, she has been at the helm of the company's retail operations, managing over 2,200 locations across 34 states.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/03/44081963/ford-february-us-sales-slide-8-9-ev-sales-jump-15-details" rel="noreferrer noopener">Ford February US Sales Slide 8.9%, EV Sales Jump 15%: Details</a>
Her career includes roles such as Executive Vice President of Regional Operations and Division President in two distinct markets. Morris began her journey with Albertsons at a store in Denver, where she started her long-standing career.
&#8220;She is highly respected across the organization and industry, with a strong track record of operational success and passion for serving our customers and communities,&#8221; said Chair of the Albertsons Cos. Board of Directors, Jim Donald.
Outlook Reaffirmed: In addition to the leadership change announcement, Albertsons has<a href="https://www.benzinga.com/25/01/42874054/grocery-giant-albertsons-q3-sales-grow-as-pharmacy-products-shine" target="_blank" rel="noreferrer noopener"> reaffirmed its financial projections</a> for 2024. The company expects Identical sales growth to be in the range of 1.8% to 2.0%.
Adjusted EBITDA is forecasted to be between $3.95 billion and $3.99 billion. The anticipated adjusted net income per Class A share is expected to be between $2.25 and $2.31 (consensus $2.29), while capital expenditures are estimated at between $1.8 billion and $1.9 billion.
The company also projects an effective income tax rate between 15% and 16%.
Price Action: ACI shares closed lower by 1.66% at $20.69 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44074819/servicenow-unveils-ai-agents-for-telecoms-in-collaboration-with-nvidia" target="_blank" rel="noreferrer noopener">ServiceNow Unveils AI Agents For Telecoms In Collaboration With Nvidia</a></li>
</ul>
Image via Shutterstock.

Management

Grocery Giant Albertsons Names Susan Morris As New CEO

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and maintains $3 price target.

HC Wainwright & Co. Reiterates Buy on Canaan, Maintains $3 Price Target

Citigroup analyst Ralph Giacobbe upgrades Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) from Neutral to Buy and raises the price target from $250 to $300.

Upgrades

Laboratory Corporation Of America Holdings

Citigroup Upgrades Labcorp Hldgs to Buy, Raises Price Target to $300

SOUN

SoundHound AI Filed Non-Timely 10-K With SEC, Reports Continued Material Weaknesses As Of Dec 31, 2024

WIIM

ESPR

Esperion Therapeutics shares are trading higher after the company reported better than expected Q4 FY24 earnings.

Citigroup analyst Joanne Wuensch downgrades Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) from Buy to Neutral and lowers the price target from $35 to $24.

TNDM

Citigroup Downgrades Tandem Diabetes Care to Neutral, Lowers Price Target to $24

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/04080258/HUGE.jpeg" alt="" class="wp-image-7077" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/04080258/HUGE.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/04080258/HUGE-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/04080258/HUGE-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The dental products and materials maker derives 70% of its revenue from China, but plans to use IPO proceeds for a new production base in Indonesia
Key Takeaways:
<ul>
<li>Huge Dental has applied for a Hong Kong IPO, reporting a net profit of 77.7 million yuan on 300 million yuan in revenue in the first three quarters of 2024</li>
<li>The dental products supplier plans to use proceeds from the listing to build a factory in Indonesia as a base for global expansion</li>
</ul>
If they frown on you in one market, then maybe they'll smile in another.
That seems to be the attitude of dental products maker&nbsp;Huge Dental Ltd., which has given up on plans to list on China's domestic A-share markets in Shanghai and Shenzhen after efforts over the past decade went nowhere. Now, the company is hoping for a warmer greeting in Hong Kong with its&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107132/documents/sehk25021900956.pdf">new application</a>&nbsp;to list on the city's the stock exchange filed late last month.
Huge Dental wasn't completely out of luck when it came to Chinese Mainland listings. The company once listed on the Beijing-based over-the-country style National Equities Exchange and Quotations (NEEQ) board as early as April 2015. But it delisted two years later amid thin trading.
It aimed to graduate to the majors with its July 2017 application to list on Shenzhen's Nasdaq-style ChiNext board for growth companies but terminated that application two years later. Not one to give up so easily, it tried again in 2019, this time on Shanghai's then-newly launched STAR market, also for growth companies, but failed once more.
Those repeated setbacks never wiped the smile from Huge Dental's face, as it hopes its third try at the big leagues will be the charm. It could very well have better luck this outing, as Hong Kong has typically been far friendlier to this type of consumer-style listing, unlike the ChiNext and STAR markets that prefer sexier growth sectors like tech and new energy.
Huge Dental's listing document shows it was founded in 2006 by Song Xin, now 52. Its main business is divided into three categories: dental clinical products, like impression-taking materials and resin adhesive materials; dental laboratory products, which mainly refers to denture restoration materials; and dental digital products. The vast majority of its revenue, around 97%, comes from the first two categories.
<h4 class="wp-block-heading">Improving margins</h4>
Huge Dental is China's largest manufacturer of elastomeric impression materials and synthetic resin teeth, based on revenue in 2023, according to third-party market data in the company's listing document. The broader dental industry has been feasting for the last decade on a new Chinese middle class that can now afford such small luxuries as dentures and other forms of synthetic teeth.
As the sector expanded, Huge Dental's revenue grew 28% from 280 million yuan ($38.6 million) in 2022 to 358 million yuan in 2023. Its revenue continued growing last year, though at a slower pace, rising 14% year-on-year to 304 million yuan in the first nine months of 2024. Its net profit similarly rose 38% from 64 million yuan in 2022 to 88.4 million yuan in 2023. The growth continued at a slower rate last year, up 6.6% in the first nine months of 2024 to 77.7 million yuan. Perhaps most importantly, the company's gross margin has also climbed steadily from 54.9% in 2022 to 59.2% in the first nine months of last year.
Huge Dental sells its products in more than 60 countries and regions, though nearly 70% of its revenue comes from its home China market. Its other major markets are Europe, accounting for about 12% of revenue, and North America, at about 10%. It plans to use IPO proceeds to buy land in Indonesia, where it wants to construct a new factory that will serve as a strategic base to further its global expansion.
<h4 class="wp-block-heading">National policy dividend</h4>
Huge Dental is lucky to be selling into the right environment, especially as many consumer sectors suffer in China's economic slowdown. On a global scale, a worldwide aging population and growing awareness of dental health have caused demand for dental medical supplies to rise sharply, valued at $37.8 billion in 2019 and expected to reach $83.7 billion in 2030, according to the listing document. China's market is especially buoyant, rising from 43.4 billion yuan in 2019 to 60.7 billion yuan in 2023, and expected to grow 15.5% annually from then to reach 166.7 billion yuan in 2030.
Government policy support has helped to boost the industry in China, with oral health recognized as a priority in the country's "Healthy China 2030" initiative. The government has encouraged development of domestically made, self-developed dental materials to nurture local brands and ween the country off imported products commonly used in the past. Huge Dental is a big beneficiary of such policies.
As Chinese brands begin to rise, they have lured away customers who traditionally bought imported products by offering prices that are generally 30% to 50% lower than those for the imports. At the same time, the domestic names are also rapidly closing the divide with foreign products in terms of quality.
A case in point is the recent unseating of U.S.-based&nbsp;Invisalign&nbsp;(ALGN.US), king of the invisible braces market, by homegrown&nbsp;Angelalign&nbsp;(6699.HK) in the Chinese market. In 2021, Angelalign's 41.1% share of China's invisible braces market made it king of the hill ahead of Invisalign, which has been in second place ever since.
<h4 class="wp-block-heading">Fierce competition</h4>
China is currently Huge Dental's mainstay, but that doesn't mean the domestic competition isn't fierce, both from emerging local and well-known global brands. Given skepticism about domestic technologies in general, Huge Dental may need to give more clinical data about its product performance and disclose more information about its patents to win over foreign investors.
To stand out from the crowd, the company must show it is constantly working to improve its products to stay ahead of rivals. In that regard, its digital dental products business might have a greater role to play in executing such a strategy. While that part of its business currently accounts for only 0.8% of its revenue, Huge Dental is planning to step up its development of intraoral scanners, 3D printers, 3D printing materials and AI-driven diagnostic tools to provide dentists with better diagnostic and treatment solutions.
Of the two major dental stocks currently listed in Hong Kong, Angelalign's price-to-earnings (P/E) ratio of 184 times is inflated by its small profit, making it an inappropriate reference. A more suitable comparison is&nbsp;Modern Dental&nbsp;(3600.HK), whose P/E stands at just 9 times. Huge Dental may be more conservative in the valuation it seeks since it's smaller than Modern Dental and could otherwise face difficulties attracting investors.
While an attractive valuation could win over investors to its IPO, the company will need a more compelling story to keep such investors over the longer run. Such a story could show the potential for "high-quality domestic substitution + digitalized products," as two major growth drivers headed into the future.

Asia

China's Huge Dental Files For Hong Kong IPO

On Tuesday, <a target="_blank" href="https://www.benzinga.com/25/03/44084767/taiwan-semiconductor-weighs-100-billion-us-investment-as-chip-war-heats-up" rel="noreferrer noopener">contract chipmaker</a> Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) announced plans to invest an additional $100 billion in advanced semiconductor manufacturing in the U.S.
Building on the company&#8217;s ongoing $65 billion investment in its advanced semiconductor manufacturing operations in Phoenix, Arizona, Taiwan Semiconductor&#8217;s total investment in the U.S. will likely reach $165 billion. The expansion includes plans for three new fabrication plants, two advanced packaging facilities, and a significant R&amp;D team center.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44087877/intel-stock-surges-as-nvidia-broadcom-test-18a-chips-amd-shows-interest" rel="noreferrer noopener">Intel Gains Traction With 18A Process As Nvidia, Broadcom Consider Manufacturing Contracts</a>
The contract chipmaker expects to create hundreds of billions of dollars in semiconductor value for AI and other cutting-edge applications. The expanded investment will likely support 40,000 construction jobs over the next four years and create tens of thousands of high-paying, high-tech jobs in advanced chip manufacturing and R&amp;D.
It will likely drive over $200 billion of indirect economic output in Arizona and across the U.S. in the next decade, the company said.
Taiwan Semiconductor&#8217;s Arizona fab currently employs more than 3,000 people on 1,100 acres of land in Arizona. The site has been in volume production since late 2024.
U.S. President Donald Trump has been a <a target="_blank" href="https://www.benzinga.com/government/regulations/25/02/44013241/taiwan-semiconductor-faces-government-scrutiny-on-overseas-ventures-amid-intel-stake-rumors" rel="noreferrer noopener">critic of Taiwan</a> since his presidential campaign days for accusing them of allegedly stealing American semiconductor business. He promised action against the country and threatened retaliatory tariffs because of Taiwan&#8217;s large trade surplus with the U.S.
IDC expects the <a target="_blank" href="https://www.benzinga.com/24/12/42480928/taiwan-semi-set-to-command-67-foundry-market-share-idc" rel="noreferrer noopener">Taiwanese contract chipmaker</a> to command a 67% share of the global foundry market in 2025, up 300 bps year over year.
Separate reports indicated the U.S. government canvassing Taiwan Semiconductor to help bail out Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) out of its woes <a target="_blank" href="https://www.benzinga.com/government/regulations/25/02/44013241/taiwan-semiconductor-faces-government-scrutiny-on-overseas-ventures-amid-intel-stake-rumors" rel="noreferrer noopener">via strategic acquisition</a>.
Meanwhile, Big Tech giants remain&nbsp;aggressively invested in&nbsp;their AI ambitions.&nbsp;Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), a key Taiwan Semiconductor client, committed over $500 billion to AI and advanced manufacturing.
Price Action:&nbsp;TSM stock traded higher by 1.48% to $175.53 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44088403/amazon-web-services-bets-big-on-india-with-82-billion-cloud-investment" target="_blank" rel="noreferrer noopener">Amazon Web Services Bets Big On India with $8.2 Billion Cloud Investment</a></li>
</ul>
Photo by wakamatsu.h via Shutterstock

AAPL

INTC

Taiwan Semiconductor Doubles Down On US Chipmaking, Plans $165 Billion Investment

Plug Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares are trading lower premarket on Tuesday after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44096388/plug-power-announces-continued-cash-flow-improvement-and-progress-on-path-to-profitability" rel="noreferrer noopener">reported fourth-quarter&nbsp;results</a>.
The company reported&nbsp;revenue of&nbsp;$191.5 million, missing <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">analyst&nbsp;estimates&nbsp;of&nbsp;$263.2 million</a>.
The company reached a pivotal milestone in electrolyzer deployments, expanded its hydrogen network, and enhanced the utilization of its manufacturing facilities.
Electrolyzer revenue escalated 583% Y/Y, aided by 5-MW system sales and a large-scale order deployment.
Customer warrant charges stood at $22.7 million, impacted by updated forecasts and the timing of customer programs.
In the fourth quarter, operating cash flow improved 46% year over year (Y/Y), led by margin expansion and better working capital efficiency.
Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/technicals/25/03/44088446/plug-power-stock-nears-oversold-territory-will-q4-earnings-be-the-turning-point" rel="noreferrer noopener">Plug Power Stock Nears Oversold Territory: Will Q4 Earnings Be The Turning Point?</a>
In the quarter, the company reported a gross margin loss of 122%, reflecting a strategic deceleration in investments for mobility, high-power stationary applications, and product development.
Despite the significant improvement in cash burn, the company said it determined that the strategic actions to temper the investment pace on certain platforms, coupled with the fact that certain markets are developing slower than expected, collectively resulted in accounting conclusions to record varied non-cash impairments of certain long-lived and intangible assets.
The company recorded $971.3 million in non-cash charges for asset impairments and bad debt provisions in the fourth quarter on strategic shifts and market demand pushouts.
These impairments are expected to lower future depreciation and amortization by an estimated <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$55 million – $60 million in 2025</a>.
Plug CEO Andy Marsh said, &#8221;While we made great strides in improving cash flows in 2024, it is clear based on market dynamics that we have to make additional strides, therefore we are initiating Project Quantum Leap to further position Plug for success in the near and long term by continuing to leverage the platforms we have built while further optimizing the Company.&#8221;
Plug Power expects Project Quantum Leap to reduce annual expenses in the range of $150 million to $200 million.
These measures are expected to include additional reductions in the workforce over the coming weeks, furthering its rooftop facility consolidations, additional reductions in discretionary spending, additional reduction and leveraging of inventory, and limiting capital expenditures to near-term critical requirements.
The company expects that taking these actions will further improve margins and cash flows and accelerate the path to profitability.&nbsp;
As of 2024, unrestricted cash stood at over $200 million. The company expects cash burn in 2025 to continue to significantly improve.
Investors can gain exposure to the stock via&nbsp;ProShares S&amp;P&nbsp;Kensho Cleantech ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTEX#NYSE">CTEX</a>).&nbsp;
Price Action: PLUG shares are down 2.00% at $1.47 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44042800/plug-power-ties-executive-compensation-plan-to-stock-performance" target="_blank" rel="noreferrer noopener">Plug Power&#8217;s High-Stakes Move: Executives Can Take Up To 75% Of Pay In Company Stock</a></li>
</ul>
Photo via Shutterstock.

Comments

Concentra Group Holdings

ニュース

パートナーシップ

ベンジンガ・グローバル